FY2022 EPS Estimates for Merck & Co., Inc. (NYSE:MRK) Increased by Analyst

Merck & Co., Inc. (NYSE:MRKGet Rating) – Research analysts at SVB Leerink upped their FY2022 earnings estimates for Merck & Co., Inc. in a report issued on Sunday, January 22nd. SVB Leerink analyst D. Graybosch now expects that the company will post earnings of $7.41 per share for the year, up from their previous forecast of $7.35. SVB Leerink has a “Outperform” rating and a $120.00 price objective on the stock. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $7.39 per share. SVB Leerink also issued estimates for Merck & Co., Inc.’s Q1 2023 earnings at $1.85 EPS, Q3 2023 earnings at $1.85 EPS, Q4 2023 earnings at $1.88 EPS, FY2023 earnings at $7.43 EPS, FY2024 earnings at $8.51 EPS, FY2025 earnings at $9.30 EPS, FY2026 earnings at $10.03 EPS and FY2027 earnings at $10.86 EPS.

Several other equities analysts also recently weighed in on MRK. Citigroup increased their price target on shares of Merck & Co., Inc. to $105.00 in a report on Tuesday, November 15th. Barclays boosted their price objective on Merck & Co., Inc. from $110.00 to $128.00 in a report on Tuesday, December 20th. Morgan Stanley lifted their price objective on shares of Merck & Co., Inc. from $91.00 to $100.00 and gave the company an “equal weight” rating in a report on Friday, October 28th. Guggenheim raised their target price on Merck & Co., Inc. from $104.00 to $111.00 and gave the company a “buy” rating in a research report on Tuesday, November 1st. Finally, Cowen upped their target price on Merck & Co., Inc. from $108.00 to $120.00 in a research note on Tuesday, January 3rd. Four equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $113.83.

Merck & Co., Inc. Stock Down 1.2 %

Merck & Co., Inc. stock opened at $108.52 on Tuesday. Merck & Co., Inc. has a fifty-two week low of $72.88 and a fifty-two week high of $115.49. The company has a market cap of $275.14 billion, a PE ratio of 18.06, a PEG ratio of 1.38 and a beta of 0.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 1.46. The business’s 50-day simple moving average is $109.70 and its two-hundred day simple moving average is $97.76.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings data on Thursday, October 27th. The company reported $1.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.18. The firm had revenue of $14.96 billion for the quarter, compared to the consensus estimate of $14.05 billion. Merck & Co., Inc. had a net margin of 25.88% and a return on equity of 46.57%. The company’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.75 EPS.

Merck & Co., Inc. Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, January 9th. Investors of record on Thursday, December 15th were given a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 2.69%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.69. The ex-dividend date was Wednesday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 48.59%.

Insider Buying and Selling

In other Merck & Co., Inc. news, insider Johannes Jacobus Oosthuizen sold 45,561 shares of the firm’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $99.47, for a total transaction of $4,531,952.67. Following the transaction, the insider now owns 18,526 shares of the company’s stock, valued at $1,842,781.22. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Johannes Jacobus Oosthuizen sold 45,561 shares of the company’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $99.47, for a total value of $4,531,952.67. Following the completion of the sale, the insider now directly owns 18,526 shares of the company’s stock, valued at $1,842,781.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kenneth C. Frazier sold 235,000 shares of the company’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $98.61, for a total transaction of $23,173,350.00. Following the transaction, the insider now owns 700,653 shares of the company’s stock, valued at approximately $69,091,392.33. The disclosure for this sale can be found here. Insiders have sold 1,165,809 shares of company stock worth $118,007,120 in the last ninety days. 0.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Smith Salley & Associates grew its holdings in Merck & Co., Inc. by 3.8% during the 2nd quarter. Smith Salley & Associates now owns 175,588 shares of the company’s stock valued at $16,008,000 after buying an additional 6,492 shares during the last quarter. Calamos Advisors LLC raised its stake in Merck & Co., Inc. by 2.8% during the second quarter. Calamos Advisors LLC now owns 649,200 shares of the company’s stock worth $59,188,000 after purchasing an additional 17,920 shares during the period. Liontrust Investment Partners LLP acquired a new position in Merck & Co., Inc. in the second quarter valued at $7,575,000. Arnhold LLC increased its stake in Merck & Co., Inc. by 33.6% during the second quarter. Arnhold LLC now owns 11,676 shares of the company’s stock worth $1,065,000 after acquiring an additional 2,934 shares during the last quarter. Finally, Center For Asset Management LLC increased its position in Merck & Co., Inc. by 151.6% during the 2nd quarter. Center For Asset Management LLC now owns 8,403 shares of the company’s stock worth $766,000 after purchasing an additional 5,063 shares in the last quarter. 72.89% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.